WHY LIGHT THERAPY?
We are delighted to announce the arrival at John Rose Eyecare of the world’s first whole body light pod – the “NovoThor” – this is the first of its kind in the UK and currently one of only 4 in Europe.
The installation of the NovoTHor will allow our clients to benefit from Red and Near Infra Red light therapy that currently is only being enjoyed by a select few elite athletes or being used for medical treatment.
AWARD WINNING WHOLE-BODY LIGHT POD
The NovoTHOR is a whole body delivery system of PBM Therapy that has been designed to deliver optimal wavelengths, power densities and dosages based on published clinical research outcomes.
The intended uses of the NovoTHOR are to redevelop muscles, or restore motion to joints, or for use as an adjunct treatment for obesity.
Photobiomodulation is currently being used in many areas of medicine - there are many photo-therapy devices that have been FDA approved for various applications involving wound healing, pain reduction and aesthetic procedures in medicine, dentistry, physiotherapy and veterinary and oncology.
However this is mainly with the use of hand held devices that only treat a small area at a time and is time consuming and difficult to treat larger areas - the NovoTHor is able to treat the whole body at the same time.
WHAT TO EXPECT FROM YOUR LIGHT POD SESSION
The treatment takes 15 minutes. We currently allow
30 minutes per booking to allow for changing. You must be able to get upstairs
A single session costs £70, however packages
can reduce this to £50.
Please note the NovoTHor Light Pod is located upstairs on the first floor -
NB: In our experience, since 2017 since the NovoTHor Light Pod was installed, we have had some feedback from our clients stating they may feel a little fatigued immediately after a session, followed by feeling much better. However, one client stated they had a migraine that felt much worse than any previous migraine they had experienced.
Photobiomodulation as a Treatment in Dry AMD
By HakanKaymak, MD; and HartmutSchwahn, PhD
The development of innovative treatments for debilitating diseases such as age-related macular degeneration (AMD) is crucial to advance patient care and to reduce burdens on patients, caregivers, and physicians. The dry, or nonexudative, form of AMD affects approximately 85% to 90% of individuals with AMD, and, until now, there have…
“Don’t Turn a Blind Eye to Macular Degeneration.” As we get older, the macula, the part of the eye responsible for our central vision, allowing us to see fine detail clearly can become damaged. The macula is crucial for activities such as reading or driving. (AMD) Macu-SAVE is a food…
John Rose Eyecare
was shortlisted for the 2013 Kingston Business Excellence Awards.